1. Home
  2. CURR vs PLX Comparison

CURR vs PLX Comparison

Compare CURR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Currenc Group Inc. Ordinary Shares

CURR

Currenc Group Inc. Ordinary Shares

SELL

Current Price

$1.88

Market Cap

208.8M

ML Signal

SELL

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

SELL

Current Price

$2.90

Market Cap

207.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CURR
PLX
Founded
2013
1993
Country
Singapore
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.8M
207.1M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
CURR
PLX
Price
$1.88
$2.90
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
243.0K
★ 990.1K
Earning Date
12-01-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.31
Revenue
$46,435,412.00
★ $52,744,000.00
Revenue This Year
$12.39
$64.22
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$9.85
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$1.65
52 Week High
$5.08
$3.19

Technical Indicators

Market Signals
Indicator
CURR
PLX
Relative Strength Index (RSI) 36.11 56.51
Support Level $1.43 $2.08
Resistance Level $3.50 $3.19
Average True Range (ATR) 0.23 0.20
MACD 0.03 0.03
Stochastic Oscillator 64.18 71.74

Price Performance

Historical Comparison
CURR
PLX

About CURR Currenc Group Inc. Ordinary Shares

Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It operates into two reportable segments, which are remittance services and sales of airtime, of which maximum revenue is generated from the Remittance segment. Geographically, the group generates the majority of its geographic revenue from Malaysia.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Share on Social Networks: